XTX Topco Ltd Raises Stock Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

XTX Topco Ltd lifted its holdings in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 1,564.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 219,819 shares of the biopharmaceutical company’s stock after acquiring an additional 206,614 shares during the period. XTX Topco Ltd owned 0.40% of Marinus Pharmaceuticals worth $118,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MRNS. JPMorgan Chase & Co. boosted its stake in Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares during the period. Virtu Financial LLC purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $36,000. Franklin Resources Inc. boosted its stake in shares of Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 1,219,871 shares during the period. Deltec Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the fourth quarter worth about $107,000. Finally, World Investment Advisors LLC acquired a new position in Marinus Pharmaceuticals in the 3rd quarter valued at about $104,000. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Stock Performance

Marinus Pharmaceuticals stock opened at $0.55 on Wednesday. The company has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals, Inc. has a one year low of $0.22 and a one year high of $1.97. The business has a fifty day moving average of $0.55 and a two-hundred day moving average of $0.54.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Marinus Pharmaceuticals in a report on Sunday. They issued a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.